Compare Old Dominion Freight Line Inc (ODFL) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Old Dominion Freight Line Inc vs Sana Biotechnology Inc — how do they compare? Old Dominion Freight Line Inc trades at $182.12 (market cap $37.71B), while Sana Biotechnology Inc trades at $3.17 (market cap $947.48M). The key difference: Old Dominion Freight Line Inc is far larger — about 39.8× Sana Biotechnology Inc's market cap, and Old Dominion Freight Line Inc pays a 0.64% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ODFL | SANA | |
|---|---|---|
Market Cap | $37.71B | $947.48M |
Sector | Industrials | Health |
52-Week High | $248.73 | $5.92 |
52-Week Low | $126.29 | $2.68 |
Enterprise Value | $37.45B | $860.73M |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Old Dominion Freight Line (ODFL) trades at $187.01, up 0.61% on the day, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue per day rose 12.4% year-over-year in August 2026, though net income margins have softened from 21.99% in 2022 to 18.62% in 2025. The balance sheet remains robust with low debt, and cash flow trends show improved net cash flow in 2026.
Outlook: ODFL's premium valuation (P/E 35.96) demands sustained execution, but analyst consensus targets $238.73 imply ~28% upside. Risks include freight volume pressure and high valuation sensitivity. Institutional buying and cost discipline support momentum, though technical weakness near support at $182 warrants caution.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
